<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054262</url>
  </required_header>
  <id_info>
    <org_study_id>TULA-TULI-2202</org_study_id>
    <secondary_id>CWRU-100211</secondary_id>
    <secondary_id>CDR0000270198</secondary_id>
    <secondary_id>TULA-T-607-004</secondary_id>
    <nct_id>NCT00054262</nct_id>
  </id_info>
  <brief_title>T900607 in Treating Patients With Unresectable Liver Cancer</brief_title>
  <official_title>A Phase II Study Of Intravenous T900607-Sodium In Subjects With Chemotherapy-Naive Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Seidman Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have&#xD;
      unresectable liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the complete and partial response rates of patients with chemotherapy-na√Øve&#xD;
           unresectable hepatocellular carcinoma treated with T900607.&#xD;
&#xD;
        -  Determine the efficacy of this drug, in terms of duration of response and time to&#xD;
           disease progression, in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Determine the safety profile of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive T900607 IV over 1 hour once weekly. Treatment continues in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T900607</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed unresectable hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  Bidimensionally measurable disease defined as at least 1 lesion that is 1 cm or more&#xD;
             in 2 dimensions by CT scan&#xD;
&#xD;
          -  Class A or B Child-Pugh liver classification&#xD;
&#xD;
          -  No prior CNS metastases or carcinomatous meningitis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3*&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3*&#xD;
&#xD;
          -  Hemoglobin at least 8.5 g/dL* NOTE: *More than 7 days since prior blood transfusions&#xD;
             or growth factors&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Albumin greater than 2.5 g/dL&#xD;
&#xD;
          -  AST and ALT no greater than 3 times ULN&#xD;
&#xD;
          -  INR no greater than 1.5 (unless receiving anticoagulants)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF at least 50%&#xD;
&#xD;
          -  No New York Heart Association class III or IV cardiac disease&#xD;
&#xD;
          -  No acute anginal symptoms&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
&#xD;
          -  No severe concurrent disease, infection, or co-morbidity that would preclude study&#xD;
             entry&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior immunotherapy for HCC&#xD;
&#xD;
          -  No concurrent therapeutic biological response modifier&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for HCC&#xD;
&#xD;
          -  No prior chemoembolization for HCC&#xD;
&#xD;
          -  No other concurrent cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 6 weeks since prior hormonal therapy (an indicator lesion must exist outside&#xD;
             the area of therapy&#xD;
&#xD;
          -  No concurrent hormonal anticancer therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for HCC&#xD;
&#xD;
          -  At least 6 weeks since prior radiofrequency ablation, selective internal radiation, or&#xD;
             embolization (an indicator lesion must exist outside the area of therapy)&#xD;
&#xD;
          -  No concurrent radiotherapy (including palliative therapy)&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 6 weeks since prior surgical resection (an indicator lesion must exist&#xD;
             outside the area of therapy)&#xD;
&#xD;
               -  Recurrence at the margin of the surgical resection is allowed&#xD;
&#xD;
          -  At least 6 weeks since prior cryosurgery&#xD;
&#xD;
          -  More than 4 weeks since other prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior investigational therapy&#xD;
&#xD;
          -  At least 6 weeks since prior intratumoral ethanol injection (an indicator lesion must&#xD;
             exist outside the area of therapy)&#xD;
&#xD;
          -  No other concurrent investigational anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna M. Brell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-1714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

